去纤苷会产生耐药吗？治疗时需要注意什么

Hepatic veno-occlusive disease is a common complication of hematopoietic stem cell transplantation. Clinical manifestations include: hepatomegaly, ascites, abdominal pain, etc. There is currently a good drug for treating this disease, which is defibrotide. Defibrotide is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), and renal or pulmonary dysfunction after hematopoietic stem cell transplantation (HSCT). In clinical trials, patients treated with defibrotide have a higher survival rate and significant therapeutic effects. The launch of this drug has brought new treatment options to many patients with hepatic veno-occlusive disease (VOD). Will resistance develop? What should I pay attention to during treatment?

Defibrotide resistance

No matter which drug it is, drug resistance will develop after long-term use, and Defibrotide is no exception. However, because each patient's disease stage and tolerance to drugs are different, the time it takes for a patient to develop drug resistance and the manifestations of drug resistance after receiving defibrotide treatment will also vary. This is mainly determined by the patient's disease progression, physical condition, and drug tolerance. Patients should seek medical treatment immediately after becoming resistant to defibrotide. Professional doctors will recommend the best treatment plan based on the patient's condition. After developing drug resistance, patients must not use drugs for treatment without authorization to avoid other adverse reactions and a negative impact on the condition.

Precautions for defibrination

Hypersensitivity reactions may occur during treatment with defibrotide, including rash, urticaria, and angioedema. Therefore, patients should be monitored for hypersensitivity reactions during treatment with this drug. If a severe hypersensitivity reaction occurs, defibrotide should be discontinued and treated according to standard of care.

Patients who are allergic to any of the drug components in Defibrotide should not use this drug to avoid other adverse reactions.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended hot articles: